NCT05376319View on ClinicalTrials.gov

PR3-AAV Resilient Remission or PRRR

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

May 7, 2024

Study Completion Date

May 7, 2024

Conditions
Granulomatosis With PolyangiitisMicroscopic PolyangiitisANCA Associated Vasculitis
Interventions
DRUG

Obinutuzumab

1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15

DRUG

Rituximab

1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

55905

Mayo Clinic Rochester, Rochester

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER